Drug intelligence / Profile preview

AVA7367

Development stage: Preclinical
Lead developer: Aviara Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AVA7367 is a small molecule dual antagonist of α4β1 (VLA-4) and α4β7 integrins, currently in IND-enabling studies for the treatment of inflammatory bowel disease (IBD) and other inflammatory conditions. Developed by Aviara Pharmaceuticals, the compound is designed to inhibit the trafficking of leukocytes to inflamed tissues by blocking their interaction with cell adhesion molecules like VCAM-1 and MAdCAM-1. By targeting both α4β1 and α4β7, AVA7367 aims to provide a more comprehensive anti-inflammatory effect compared to agents that target only one of these integrins, potentially offering improved efficacy in conditions like Crohn's disease and ulcerative colitis.

Other names: AVA7367AVA-7367AVA 7367

Targets

α4β1 (Integrin α4β1)α4β7 (Integrin alpha-4 beta-7 heterodimer)

Beyond the preview

Go deeper on AVA7367.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVA7367.

Explore the full profile